Therapeutics News

Santen and UBE announced the FDA approval of Omlonti for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

LAS VEGAS – Optometrists should be aware of the current concern for overprescribing of opiates, Marc D. Myers, Coatesville VA Medical Center, said at Vision Expo West.

MONTEREY, Calif. — The aqueous humor is important for diagnosis, prognosis and objective monitoring of treatment response in cases of retinoblastoma, Jesse L. Berry, MD, told colleagues here.

MONTEREY, Calif. — Interferon alpha-2b, 5-fluorouracil and mitomycin C can all be used topically for conjunctival tumors, Lauren A. Dalvin, MD, said at the Women in Ophthalmology Summer Symposium.

With a new pharmaceutical treatment option, my conversations with presbyopic patients have gotten a lot more exciting.

Reproxalap 0.25% ophthalmic solution achieved primary and secondary endpoints in a trial investigating treatment of dry eye disease, Aldeyra Therapeutics announced in a press release.

Once-daily fixed combination bimatoprost, timolol and brimonidine more effectively reduced peak IOP compared with a twice-daily regimen in patients with primary open-angle glaucoma, according to a study in the Journal of Glaucoma.

About a year ago, the ER called over to the eye clinic and said a patient had asked to be seen because he was having double vision.

NEW YORK – Either a prostaglandin or selective laser trabeculoplasty is an effective primary treatment for glaucoma, “but once you get past the primary therapy, there are 44,000 different combinations of glaucoma medications you can prescribe,” said a speaker here at Vision Expo East.

DENVER – Bilastine 0.6% ophthalmic solution was shown in a phase 3 trial to be comfortable and effective in patients with allergic conjunctivitis, Paul J. Gomes, of Ora Inc. said here at ARVO.